Statins and inflammatory bowel disease: Where do we stand?

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) is a growing global health concern requiring novel therapeutic strategies.
• Statins, widely used for lipid-lowering, possess immunomodulatory properties with potential anti-inflammatory effects.
• These pleiotropic effects include inhibiting T-cell activation and leukocyte infiltration, suggesting a role in autoimmune conditions.

Purpose of the Study:

• To review experimental findings on statins' effects on inflammation.
• To critically evaluate epidemiological evidence for statins in IBD prevention and treatment.

Main Methods:

• Literature review of experimental studies in animal models of colitis.
• Appraisal of epidemiological and clinical studies investigating statins in IBD.

Main Results:

• Experimental studies indicate statins can reduce inflammation in animal models of colitis.
• Clinical studies on statins for IBD show limitations and conflicting results regarding disease modification and prevention.
• Epidemiological data is currently insufficient to confirm statins' efficacy in IBD.

Conclusions:

• While experimental data is promising, robust clinical evidence is lacking.
• Statins are not yet supported for IBD prevention or treatment based on current evidence.
• Further high-quality research is essential to clarify the role of statins in IBD management.